🇺🇸 FDA
Patent

US 12421231

Azaindole derivatives and their use as ERK kinase inhibitors

granted A61PA61P25/00A61P29/00

Quick answer

US patent 12421231 (Azaindole derivatives and their use as ERK kinase inhibitors) held by AGV Discovery expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
AGV Discovery
Grant date
Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P25/00, A61P29/00, A61P31/18, A61P35/00